Hep B

On Tuesday, Jefferies issued a company note on Gilead Sciences, Inc. (NASDAQ: GILD) after an "R&D Day" showed that potential drug candidates in the hepatitis B market may prove effective. Currently, analysts at Jefferies rate Gilead as a Hold with an $100 price target. Brian Abrahams and...